Shares of Orthofix International N.V. (NASDAQ:OFIX) have been assigned an average recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $52.75.

OFIX has been the topic of a number of analyst reports. Langenberg & Company reiterated a “buy” rating and set a $53.25 price objective on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. Zacks Investment Research upgraded Orthofix International N.V. from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. BTIG Research initiated coverage on Orthofix International N.V. in a research report on Wednesday, June 21st. They set a “buy” rating and a $52.00 price objective on the stock. Ladenburg Thalmann Financial Services initiated coverage on Orthofix International N.V. in a research report on Wednesday, June 14th. They set a “buy” rating and a $53.25 price objective on the stock. Finally, TheStreet upgraded Orthofix International N.V. from a “c+” rating to a “b-” rating in a research report on Tuesday, August 8th.

Shares of Orthofix International N.V. (NASDAQ OFIX) opened at 47.85 on Friday. Orthofix International N.V. has a one year low of $32.51 and a one year high of $50.40. The stock’s 50 day moving average price is $47.80 and its 200 day moving average price is $43.18. The stock has a market capitalization of $869.43 million, a PE ratio of 112.06 and a beta of 0.22.

Orthofix International N.V. (NASDAQ:OFIX) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.01. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. The firm had revenue of $108.90 million for the quarter, compared to the consensus estimate of $102.94 million. During the same quarter last year, the business posted $0.41 earnings per share. The firm’s revenue was up 4.6% compared to the same quarter last year. Equities research analysts predict that Orthofix International N.V. will post $1.56 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/09/24/orthofix-international-n-v-ofix-given-consensus-recommendation-of-buy-by-brokerages.html.

In other news, CFO Rice Doug sold 7,353 shares of Orthofix International N.V. stock in a transaction on Monday, September 11th. The stock was sold at an average price of $49.46, for a total value of $363,679.38. Following the completion of the sale, the chief financial officer now directly owns 44,743 shares of the company’s stock, valued at $2,212,988.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Bradley V. Niemann sold 6,956 shares of Orthofix International N.V. stock in a transaction on Monday, September 11th. The shares were sold at an average price of $49.44, for a total value of $343,904.64. Following the completion of the sale, the insider now directly owns 40,178 shares of the company’s stock, valued at $1,986,400.32. The disclosure for this sale can be found here. Insiders sold 23,406 shares of company stock worth $1,138,531 in the last 90 days. Company insiders own 5.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP acquired a new position in Orthofix International N.V. during the 1st quarter worth $20,021,000. Vanguard Group Inc. grew its stake in Orthofix International N.V. by 18.6% during the 1st quarter. Vanguard Group Inc. now owns 1,815,948 shares of the medical device company’s stock worth $69,278,000 after purchasing an additional 284,482 shares in the last quarter. Teachers Advisors LLC grew its stake in Orthofix International N.V. by 676.2% during the 1st quarter. Teachers Advisors LLC now owns 276,340 shares of the medical device company’s stock worth $10,542,000 after purchasing an additional 240,740 shares in the last quarter. Paradice Investment Management LLC acquired a new position in Orthofix International N.V. during the 2nd quarter worth $6,642,000. Finally, Principal Financial Group Inc. acquired a new position in Orthofix International N.V. during the 1st quarter worth $5,359,000. 94.40% of the stock is owned by institutional investors and hedge funds.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Analyst Recommendations for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.